Indivior (INDV)

Executive Summary

Indivior is a global pharmaceutical leader specializing in treatments for substance use disorders, particularly opioid use disorder (OUD), with a growing focus on serious mental illnesses. Its core commercial portfolio includes Sublocade (buprenorphine extended-release injection) and Perseris (risperidone for schizophrenia), both of which have driven steady revenue growth. The company recently completed its redomiciliation from the United Kingdom to the United States, which is expected to enhance operational efficiency and align its corporate structure with its primary market. Indivior's pipeline is anchored by next-generation OUD therapies, including a potential buprenorphine implant and new formulations aimed at improving patient compliance and outcomes. Despite facing generic competition for its earlier products and ongoing litigation related to past marketing practices, Indivior maintains a strong competitive position in addiction medicine, supported by a dedicated sales force and robust intellectual property. The company's strategic focus on underserved patient populations and its commitment to expanding access to medication-assisted treatment position it well for sustained growth in a market supported by favorable regulatory tailwinds.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on Sublocade label expansion for moderate OUD65% success
• Q2 2026Launch of next-generation buprenorphine implant (INDV-6001)70% success
• Q1 2026Resolution of outstanding litigation related to Suboxone marketing80% success